AP1AR Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population of the human colorectal adenocarcinoma cell line HT29, with targeted disruption of the AP1AR gene. This polyclonal pool provides a genetically heterogeneous loss-of-function model, bypassing single-cell cloning and enabling population-level functional studies of AP1AR in cancer-relevant signaling.
The HT29 cell line was derived from a primary colorectal adenocarcinoma and is widely employed as a model for intestinal epithelial biology and colorectal cancer. HT29 cells grow as adherent epithelia and can be induced to differentiate into enterocyte-like cells. They harbor oncogenic mutations in APC, TP53, and BRAF (V600E), conferring constitutive MAPK pathway activation and providing a clinically relevant background for studying tumorigenesis and signaling dependencies.
AP1AR (Adaptor-related protein complex 1 associated regulatory protein) modulates AP-1 transcription factor activity through direct interaction with c-FOS and c-JUN. It functions downstream of MAPK/ERK and JNK signaling and influences transcription of AP-1 target genes, including MMPs, cyclins, and cytokines. Through this mechanism, AP1AR regulates cell proliferation, differentiation, and apoptosis, processes frequently subverted in cancer. The interacting partner profilin (PFN1) suggests additional links to cytoskeletal reorganization.
In HT29 cells, AP1AR knockout allows dissection of AP-1-dependent transcriptional networks in the context of oncogenic APC, TP53, and BRAF mutations. Loss of AP1AR is anticipated to alter expression of proliferation- and apoptosis-regulating genes, offering insights into AP-1-driven mechanisms of colorectal cancer progression and metastasis. The polyclonal nature of the knockout pool may better mimic tumor heterogeneity, facilitating identification of population-level vulnerabilities and drug sensitivity patterns.
This knockout model supports a broad suite of applications: Western blotting and co-immunoprecipitation for AP-1 complex analysis, RT-qPCR and RNA-seq for transcriptomic profiling, MTT, CellTiter-Glo, and Annexin V staining for viability and apoptosis, and Transwell assays for migration and invasion. Drug sensitivity testing with chemotherapeutics and epithelial barrier function studies are also readily performed. For orders and technical inquiries, please contact Ascent Research.
